Inogen (NASDAQ:INGN) Azioni

INOGEN INC

Inogen

Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.

B. Riley Securities analyst Anderson Schock initiates coverage on Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) with a Buy rating and announces Price Target of $14.

News

Price Target

Initiation

Analyst Ratings

INGN

B. Riley Securities Initiates Coverage On Inogen with Buy Rating, Announces Price Target of $14

<h3>Gainers</h3>
<ul>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock increased by 97.3% to $0.45 during Tuesday's after-market session. The company's market cap stands at $4.9 million. </li>
<li>Serina Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SER#AMEX">SER</a>) stock moved upwards by 23.08% to $7.25. The company's market cap stands at $72.2 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock rose 11.08% to $0.26. The company's market cap stands at $1.1 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock increased by 10.12% to $0.87. The company's market cap stands at $3.1 million. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) stock moved upwards by 7.97% to $1.75. The market value of their outstanding shares is at $30.6 million. </li>
<li>SunLink Health Systems (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SSY#AMEX">SSY</a>) shares moved upwards by 7.07% to $1.06. The market value of their outstanding shares is at $7.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares fell 18.4% to $0.12 during Tuesday's after-market session. </li>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) shares decreased by 14.92% to $2.51. The market value of their outstanding shares is at $23.6 million. </li>
<li>CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) shares declined by 14.08% to $0.93. The market value of their outstanding shares is at $38.7 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) stock decreased by 9.88% to $0.25. The market value of their outstanding shares is at $15.1 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock decreased by 6.26% to $1.2. The company's market cap stands at $85.8 million. </li>
<li>Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) shares declined by 5.52% to $6.25. The company's market cap stands at $168.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CARM

CTOR

GELS

IMNN

NCNA

NUWE

VTAK

WINT

12 Health Care Stocks Moving In Tuesday's After-Market Session

Needham analyst Mike Matson upgraded Inogen, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) from Hold to Buy, <a target="_blank" href="https://www.benzinga.com/quote/INGN/analyst-ratings" rel="noreferrer noopener">with a price forecast of $12</a>.
On May 7, the company<a href="https://www.benzinga.com/pressreleases/25/05/b45265755/inogen-announces-first-quarter-2025-financial-results" target="_blank" rel="noreferrer noopener"> reported its first-quarter results.</a>
Total revenue in the quarter was $82.3 million, an increase of 5.5% from the prior-year period, or 7.1% at constant currency rates, due to higher demand from international and domestic business-to-business customers.
Matson highlighted the turnaround efforts led by the company&#8217;s new management team, which remains underappreciated by the market.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/upgrades/25/05/45562777/this-united-rentals-analyst-turns-bullish-here-are-top-5-upgrades-for-thursday" rel="noreferrer noopener">This United Rentals Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday</a>
The company has returned to mid-single-digit revenue growth, with expectations for further acceleration in the second half of 2025 and into 2026.
Matson also notes improvements in margin performance and highlights management&#8217;s strategy to expand Inogen&#8217;s focus beyond its core offerings into a more diversified respiratory device portfolio, which introduces multiple new avenues for growth.
He added that management anticipates nearing adjusted EBITDA breakeven in 2025, which he views as a positive indicator of progress.
Matson writes that the decline in Inogen&#8217;s direct-to-consumer sales has primarily stemmed from a smaller DTC sales force.
The analyst also projects margins to improve further as direct-to-consumer sales stabilize or return to growth, especially after the impact of the sales force reduction is fully reflected in the fourth quarter of 2025.
Price Action: INGN shares are trading higher by 14% to $6.795 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45551302/5-undervalued-stocks-to-buy-on-china-tariff-cuts" target="_blank" rel="noreferrer noopener">5 Undervalued Stocks To Buy On China Tariff Cuts</a></li>
</ul>
Photo: Shutterstock

Equities

Markets

Trading Ideas

General

Inogen Upgraded: Analyst Sees Growth, EBITDA Breakthrough

WIIM

Inogen shares are trading higher after Needham upgraded the stock from Hold to Buy and announced a $12 price target.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham analyst Mike Matson upgraded the rating for Inogen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) from Hold to Buy and announced a $12 price target. Inogen shares closed at $5.96 on Wednesday. <a href="https://www.benzinga.com/quote/INGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Ken Newman upgraded United Rentals, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>) from Sector Weight to Overweight and announced a price target of $865. United Rentals shares closed at $695.80 on Wednesday. <a href="https://www.benzinga.com/quote/URI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Matthew Boss upgraded the rating for Urban Outfitters, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) from Neutral to Overweight and raised the price target from $63 to $78. Urban Outfitters shares closed at $59.60 on Wednesday. <a href="https://www.benzinga.com/quote/URBN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Joanne Wuensch upgraded Integer Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITGR#NYSE">ITGR</a>) from Neutral to Buy and raised the price target from $133 to $140. Integer Holdings shares closed at $118.88 on Wednesday. <a href="https://www.benzinga.com/quote/itgr/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst Joshua Reilly upgraded the rating for Zoom Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) from Hold to Buy and announced a $100 price target. Zoom shares closed at $82.27 on Wednesday. <a href="https://www.benzinga.com/quote/zm/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying URI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22074323/image-283-1024x587.png" alt="" class="wp-image-924234" style="width:629px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22074323/image-283-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22074323/image-283-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22074323/image-283-768x441.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22074323/image-283.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45540545/jim-cramer-recommends-not-buying-mosaic-doesnt-like-this-industrial-stock">Jim Cramer Recommends Not Buying Mosaic, Doesn&#8217;t Like This Industrial Stock</a></li>
</ul>
Photo via Shutterstock

Upgrades

Pre-Market Outlook

ITGR

URBN

This United Rentals Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Needham analyst Mike Matson upgrades Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) from Hold to Buy and announces $12 price target.

Needham Upgrades Inogen to Buy, Announces $12 Price Target

Inogen shares are trading lower after the company reported Q1 financial results and issued Q2 sales guidance below estimates. Also, Stifel maintained a Hold rating on the stock and lowered its price target from $10 to $7.

Stifel analyst Mathew Blackman maintains Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) with a Hold and lowers the price target from $10 to $7.

Stifel Maintains Hold on Inogen, Lowers Price Target to $7

Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) sees Q2 sales of $89.000 million-$91.000 million vs $92.73 million analyst estimate.

Guidance

Inogen Sees Q2 Sales $89.000M-$91.000M vs $92.73M Est

Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) affirms FY2025 sales outlook from $352.00 million-$355.00 million to $352.00 million-$355.00 million vs $352.81 million estimate.

Inogen Affirms FY2025 Sales Guidance of $352.00M-$355.00M vs $352.81M Est

Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.50) by 78 percent. This is a 75.56 percent increase over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $82.28 million which beat the analyst consensus estimate of $79.55 million by 3.43 percent. This is a 5.45 percent increase over sales of $78.03 million the same period last year.

Earnings

Earnings Beats

Inogen Q1 Adj. EPS $(0.11) Beats $(0.50) Estimate, Sales $82.28M Beat $79.55M Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

Needham analyst Mike Matson reiterates Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Inogento Hold

Medical Technology company Inogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) reported a fourth-quarter adjusted EPS loss of 24 cents, compared to a loss of 83 cents a year ago, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss of 61 cents</a>.
The company reported sales of $80.1 million, beating the consensus of $73.9 million.
Total revenue in the fourth quarter of 2024 increased 5.5% year over year, primarily driven by higher demand and new customers in international and domestic business-to-business sales, partially offset by lower direct-to-consumer sales and lower rental revenue as a result of the company's initiatives to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43956475/inogen-announces-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">enhance overall profitability</a>.
"2024 was a stellar year for Inogen. With our new leadership team in place, we returned the company to growth, achieved significant milestones, and made meaningful steps towards profitability," said Kevin Smith, president and CEO. "With our leading portfolio of innovative respiratory care products, the pending introduction of Simeox in the U.S. and our recently announced collaboration with Yuwell, we believe we are well positioned to drive future growth, profitability, and sustained success."
Adjusted EBITDA loss was $3.6 million in the fourth quarter of 2024 compared to $17.3 million a year ago.
Guidance: Inogen expects first quarter 2025 sales of $79 million-$81 million versus consensus of $78.1 million.
The company expects fiscal year 2025 sales of $352 million-$355 million versus a consensus of $344.61 million.
Analyst Reaction:
<ul>
<li>JP Morgan writes, &#8220;With initial guidance for 1Q25 also starting off a step above the Street, we view today as another step forward towards what we hope to be fully normalized trends in 2H25 ahead of more meaningful contribution from strategic initiatives in 2026+.&#8221;</li>
<li>Analyst Robbie Marcus notes that while the company has a strong product in the underdeveloped POC market, its short-term outlook is uncertain. Supply challenges remain unresolved, and another sales team restructuring adds to the uncertainty.</li>
<li>JP Morgan maintains the Underweight rating with a <a href="https://www.benzinga.com/quote/INGN/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $10</a>.</li>
<li>Needham analyst Mike Matson reiterates Inogen with a Hold rating.</li>
<li>William Blair says, &#8220;Despite the softer DTC and rental segments, Inogen continues to see strength in its B2B segments in the U.S. and internationally. In our view, strength in this segment is durable and, although stepping down in 2025 off tougher comps, should continue to drive performance.&#8221;</li>
<li>Analyst Margaret Kaczor Andrew says the company is on a clear path to profitability and will soon benefit from recent management-driven changes in strategy, culture, and organization.</li>
</ul>
Price Action: INGN stock reached as high as $11.85 during the premarket trading before falling 9.45% to $8.60 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/02/43972083/amazons-25-billion-robotics-push-targets-cost-savings-ai-growth-and-temu-competition-report" target="_blank" rel="noreferrer noopener">Amazon&#8217;s $25 Billion Robotics Push Targets Cost Savings, AI Growth And Temu Competition: Report</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Health Care

What's Going On With MedTech Focused Inogen Stock On Wednesday?

Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) sees FY2025 sales of $352.000 million-$355.000 million vs $344.61 million analyst estimate.

Inogen Sees FY2025 Sales $352.000M-$355.000M vs $344.61M Est

Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) sees Q1 sales of $79.000 million-$81.000 million vs $78.08 million analyst estimate.

Inogen Sees Q1 Sales $79.000M-$81.000M vs $78.08M Est

Inogen shares are trading higher after the company reported better-than-expected Q4 financial results.

Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.61) by 60.66 percent. This is a 71.08 percent increase over losses of $(0.83) per share from the same period last year. The company reported quarterly sales of $80.08 million which beat the analyst consensus estimate of $73.91 million by 8.35 percent. This is a 5.51 percent increase over sales of $75.90 million the same period last year.

Inogen Q4 Adj $(0.24) Beats $(0.61) Estimate, Sales $80.08M Beat $73.91M Estimate

Press Releases

Inogen Announces Third Quarter 2024 Financial Results

Inogen Receives FDA 510(k) Clearance for SIMEOX 200 Airway Clearance Device

Inogen Announces Preliminary Fourth Quarter and Full Year 2024 Revenue

Inogen Expands Product Portfolio, Global Reach and Innovation Pipeline Through Strategic Collaboration With Yuwell

Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

Inogen Announces Fourth Quarter and Full Year 2024 Financial Results

Inogen To Present at 24th Annual Needham Virtual Healthcare Conference

Inogen to Report First Quarter 2025 Financial Results on May 7, 2025

Inogen Announces First Quarter 2025 Financial Results

Inogen Introduces Voxi 5 Stationary Oxygen Concentrator: Setting a New Standard in Affordable, Durable Oxygen Therapy

Comments

Inogen

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO